Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 14/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3328139 | 0.92 | P2RY12 (0.51) | P2RY12CYP2C9CYP3A4ALDH1A1 | |
| SCHEMBL3329147 | 0.91 | P2RY12 (0.56) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3324571 | 0.89 | P2RY12 (0.42) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3226916 | 0.87 | ALDH1A1 (0.55) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3208916 | 0.84 | P2RY12 (0.62) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4886882 | 0.84 | P2RY12 (0.48) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4738057 | 0.82 | P2RY12 (0.47) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4786405 | 0.79 | P2RY12 (0.48) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL4786928 | 0.79 | P2RY12 (0.44) | P2RY12CYP2C9CYP3A4CHRM2DRD3 | |
| SCHEMBL3326567 | 0.79 | P2RY12 (0.50) | P2RY12CYP2C9CYP3A4ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137277-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| WO-2010005384-A1 | KETONE PYRIDINE ANALOGUES AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | ASTRAZENECA AB (SE) | 2010-01-14 | — | — | WO | disclosed |
| EP-2111400-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | AstraZeneca AB (SE) | 2009-10-28 | — | — | EP | disclosed |
| US-20080200448-A1 | reversible and selective purinergic receptor P2Y12 antagonists; anticoagulants; cardiovascular disorders; e.g. ethyl 2-acetoxy-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyanonicotinate | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| US-20080171732-A1 | New Pyridine Analogues IX 519 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008085117-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008085119-A1 | NEW PYRIDINE ANALOGUES VIII 518 | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171732-A1 | New Pyridine Analogues IX 519 | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885CYP2C9 114/4885CYP3A4 451/4885 |
| US-20080200448-A1 | reversible and selective purinergic receptor P2Y12 antagonists; anticoagulants; cardiovascular disorders; e.g. ethyl 2-acetoxy-6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyanonicotinate | P2RY12, P2RY13, P2RY11 | P2RY12 1/4885CYP2C9 759/4885CYP3A4 1977/4885 |
| US-20100137277-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885CYP2C9 964/4885CYP3A4 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.